Epidarex Capital
Epidarex invests in early-stage, high growth life science and health technology companies in under-ventured markets within the UK and them.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Epidarex Capital Information
Geographic Data
Address: 7910 Woodmont Ave
City: Bethesda
State: MD
Zip: 20814
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$206M
Social
Linkedin
Crunchbase
Metrics
6,777,196Website Global Rank
797Website Monthly Traffic
Twitter Followers
Description
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, international corporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Contact Phone:
+13012985455
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2018 | AdoRx Therapeutics | Series A | 0 |
| 2/2016 | Apellis Pharmaceuticals | Series D | 47M |
| 11/2022 | Nyra Medical | Series A | 20M |
| 7/2015 | Confluence Life Sciences | Series B | 2.4M |
| 2/2015 | Enterprise Therapeutics | Series A | 2.5M |
| 3/2016 | Topas Therapeutics | Series A | 0 |
| 11/2019 | Lunac Therapeutics | Series A | 3.4M |
| 6/2018 | NodThera | Series A | 40M |
| 4/2015 | Clyde Biosciences | Series A | 2.9M |
| 1/2021 | Theolytics | Series A | 6.8M |
| 1/2017 | Eternygen | Series A | 8.5M |
| 5/2022 | Transine Therapeutics | Seed Round | 0 |
| 3/2022 | Epsilogen | Series B | 0 |
| 11/2021 | Dunad Therapeutics | Series A | 0 |
| 5/2015 | Funderbeam | Seed Round | 550.6k |
| 10/2021 | Leucid Bio | Series A | 15.9M |
| 7/2021 | Macomics | Seed Round | 0 |
| 5/2021 | Lunac Therapeutics | Venture Round | 0 |
| 11/2022 | Nyra Medical | Series A | 0 |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 8/2022 | RapidPulse | Series A | 0 |
| 11/2016 | Enterprise Therapeutics | Venture Round | 5M |
| 6/2021 | RapidPulse | Series A | 0 |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 9/2020 | Libra Therapeutics | Series A | 29M |
| 5/2015 | Enterprise Therapeutics | Series A | 3.8M |
| 11/2018 | Epsilogen | Series A | 6.4M |
| 8/2017 | Apellis Pharmaceuticals | Series E | 0 |
| 6/2020 | NodThera | Series B | 55M |
| 6/2017 | Epsilogen | Series A | 2.5M |
| 3/2021 | Dunad Therapeutics | Seed Round | - |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 1/2021 | Slate Bio | Seed Round | 0 |
| 4/2022 | Kynos Therapeutics | Seed Round | 0 |
| 2/2014 | Edinburgh Molecular Imaging | Series A | 6.6M |
| 6/2016 | Mironid | Series A | 6.2M |
| 11/2015 | Caldan Therapeutics | Series A | 6.8M |
| 2/2014 | Confluence Life Sciences | Series A | 1M |
| 7/2020 | Macomics | Seed Round | 4M |
| 12/2014 | Sirakoss | Series A | 4.8M |
| 5/2022 | Transine Therapeutics | Seed Round | 0 |
| 4/2022 | Kynos Therapeutics | Seed Round | 0 |
| 3/2022 | Epsilogen | Series B | 0 |
| 11/2021 | Dunad Therapeutics | Series A | 0 |
| 10/2021 | Leucid Bio | Series A | 0 |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 7/2021 | Macomics | Seed Round | 0 |
| 6/2021 | RapidPulse | Series A | 0 |
| 5/2021 | Lunac Therapeutics | Venture Round | 0 |
| 3/2021 | Dunad Therapeutics | Seed Round | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
